STOCK TITAN
  1. Home
  2. News
  3. GRFS

Grifols SA - GRFS STOCK NEWS

Welcome to our dedicated news page for Grifols SA (Ticker: GRFS), a resource for investors and traders seeking the latest updates and insights on Grifols SA.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Grifols SA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Grifols SA's position in the market.

News
Grifols 2023 Annual Report on Form 20-F filed with the SEC
Rhea-AI Summary
Grifols, S.A. has filed its 2023 Annual Report on Form 20-F with the SEC, offering insights into its governance practices and financial performance. The company, a prominent player in the healthcare sector specializing in plasma-derived medicines, aims to provide transparency to investors through this filing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
none
-
News
Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.
Rhea-AI Summary
Grifols commemorates five decades of producing life-altering plasma-derived medications for patients at its primary facility in Clayton, North Carolina. The establishment of the Clayton site in 2011 propelled Grifols to become a prominent player in the plasma industry, fostering continuous business expansion. The flagship Grifols campus epitomizes the company's dominance in plasma therapeutics, generating significant positive impact on patient care and medical advancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
none
-
News
Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening
Rhea-AI Summary
Grifols announces CE mark for Procleix ArboPlex Assay, a test to detect major arboviruses in blood donors, enhancing transfusion safety. The test addresses a significant public health concern due to the spread of arboviruses like dengue and Zika. Grifols aims to improve donor screening efficiency and safety with this innovative solution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
none
News
Grifols announces positive topline phase 3 fibrinogen clinical trial results
Rhea-AI Summary
Grifols announces positive results from Biotest's phase 3 clinical trial for fibrinogen concentrate BT524, showing efficacy in treating acquired fibrinogen deficiency. The regulatory approval process in Europe and the United States is set to begin in Q4 2024, potentially tapping into an USD 800 million market. Grifols' robust innovation strategy is highlighted, balancing internal and external investments to build a diversified portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.34%
Tags
clinical trial
-
News
Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency
Rhea-AI Summary
Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS) completes Cohort 1 of Phase 1/2 study evaluating Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15%, a potential breakthrough treatment for alpha1-antitrypsin deficiency. The study aims to demonstrate the effectiveness of a subcutaneous approach compared to intravenous therapy, offering patients the convenience of administering medication from home. This milestone has significant implications for alpha-1 patients, potentially revolutionizing the management of AAT deficiency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
clinical trial
-
News
Bloodbuy Announces Agreement with Cerus Corporation to Offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex on its Digital Marketplace
Rhea-AI Summary
Healthcare software and services company Bloodbuy has entered into an agreement with Cerus Corporation to offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex (IFC) on its online marketplace. IFC is a pathogen reduced blood component for fibrinogen supplementation with a 5-day post-thaw shelf life. The agreement aims to enhance patient outcomes and address inventory challenges in hospitals and blood centers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
none
News
Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTAD
Rhea-AI Summary
Araclon Biotech announced positive results from its Phase 2 trial of ABvac40, an active vaccine for the treatment of early-stage Alzheimer's disease. The trial met primary endpoints, confirming the vaccine's safety, tolerability, and robust immune response against the Aβ40 peptide. ABvac40 also showed a 38% reduction in disease progression compared to placebo, as measured by the Mini-Mental State Examination score. The vaccine's unique design targets the C-terminal end of the Aβ40 peptide, potentially preventing harmful reactions and immune triggers. The prevalence of Alzheimer's disease is expected to double by 2050 in the U.S. alone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.96%
Tags
clinical trial
-
News
Grifols Accelerates Healthcare Innovation with Google Cloud’s AI and Analytics
Rhea-AI Summary
Grifols (GRF, GRF.P, GRFS) collaborates with Google Cloud to utilize AI technologies, including large language models, to accelerate the development of new biopharma therapeutics. The partnership aims to enhance Grifols' therapeutic pipeline and innovation culture, leveraging AI across the drug development life cycle to reduce time-to-market for novel treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.96%
Tags
AI
-
News
Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
clinical trial
News
Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.68%
Tags
clinical trial
Stock GRFS logo
Grifols SA

Nasdaq:GRFS

GRFS Rankings

#1295 Ranked by Market Cap
#792 Ranked by Stock Gains
N/A Ranked by Dividends

GRFS Stock Data

5.58B
546.96M
49.36%
0.88%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Spain
Barcelona

About GRFS

for more than 75 years, grifols has been improving the health and well-being of people. our patients are our priority, and our commitment to their health has enabled us to become a global healthcare leader with presence in more than 100 countries. the grifols legacy embodies a spirit of innovation and a forward thinking approach and establish us as an international benchmark in the plasma collection market, the production of plasma derived therapies and transfusion medicine. grifols has three business divisions: bioscience brings together all plasma related activities including research, development, collection, production and sales of life-saving plasma derived therapies. diagnostic provides innovative solutions to support safe and compatible transfusions, monitor therapies, and detect infectious and autoimmune diseases. research novel technologies to further improve treatment outcomes and laboratory efficiency. hospital specializes in non-biological pharmaceutical products. t